ALECTOR Reports USD 56.2 Million in Revenue for Q2 FY2023, Down 29.6% Year-on-Year
August 7, 2023
🌥️Earnings Overview
ALECTOR ($NASDAQ:ALEC) announced on June 30, 2023 that their earnings results for the second quarter of FY2023 had total revenue of USD 56.2 million, a decrease of 29.6% year-over-year. Net income for the quarter was USD 1.4 million, a drop of 86.0% compared to the same quarter in 2023.
Analysis
GoodWhale has recently conducted an analysis of ALECTOR‘s wellbeing. According to Star Chart, ALECTOR’s overall health score is 5/10 with regard to its cashflows and debt. This indicates that ALECTOR might be able to pay off its debt and fund future operations. In addition, ALECTOR is categorized as a ‘rhino’ type of company, which suggests that it has achieved moderate revenue or earnings growth. Given the analysis, it can be assumed that ALECTOR is strong in asset and growth, medium in profitability, and weak in dividend. Therefore, investors looking for long-term gains might be interested in this type of company. For those who are looking for short-term returns however, this might not be the right choice. All in all, ALECTOR appears to have some potential with regard to its cashflow and debt management. With proper financial management and innovative solutions, the company may be able to maximize its potential and ensure sustainable growth in the future. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Alector. ALECTOR_Reports_USD_56.2_Million_in_Revenue_for_Q2_FY2023_Down_29.6_Year-on-Year”>More…
| Total Revenues | Net Income | Net Margin |
| 102.06 | -143.06 | -140.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Alector. ALECTOR_Reports_USD_56.2_Million_in_Revenue_for_Q2_FY2023_Down_29.6_Year-on-Year”>More…
| Operations | Investing | Financing |
| -189.53 | 145.8 | 3.08 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Alector. ALECTOR_Reports_USD_56.2_Million_in_Revenue_for_Q2_FY2023_Down_29.6_Year-on-Year”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 708.74 | 512.43 | 2.34 |
Key Ratios Snapshot
Some of the financial key ratios for Alector are shown below. ALECTOR_Reports_USD_56.2_Million_in_Revenue_for_Q2_FY2023_Down_29.6_Year-on-Year”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 75.0% | – | -153.7% |
| FCF Margin | ROE | ROA |
| -190.5% | -51.7% | -13.8% |
Peers
The competition among Alector Inc, Trevi Therapeutics Inc, Allakos Inc, and Axsome Therapeutics Inc is fierce. All four companies are vying for a piece of the pie in the rapidly growing field of biotechnology. Alector Inc is a leading player in the space, with a strong portfolio of products and a proven track record of success. Its competitors are all looking to make a name for themselves in the industry, and each has its own unique strengths and weaknesses. Ultimately, only time will tell who will come out on top in this highly competitive market.
– Trevi Therapeutics Inc ($NASDAQ:TRVI)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of nalbuphine ER to treat serious neurological and psychiatric disorders. The company’s product candidates include Nalbuphine ER for the treatment of pruritus, and Nalbuphine ER for the treatment of major depressive disorder. It has a market cap of 104.4M as of 2022 and a return on equity of -52.73%.
– Allakos Inc ($NASDAQ:ALLK)
Allakos Inc is a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic antibodies for the treatment of allergic, inflammatory, and proliferative diseases. The company’s market cap is $502.43 million as of 2022, and its return on equity is 15.96%. Allakos was founded in 2006 by Jonathan Drachman, a medical doctor and entrepreneur. Drachman serves as the company’s CEO.
– Axsome Therapeutics Inc ($NASDAQ:AXSM)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in developing novel therapies for the management of central nervous system disorders. The company’s lead product candidate, AXS-05, is in Phase III clinical development for the treatment of Alzheimer’s disease agitation.
Summary
ALECTOR is a company that investors should keep an eye on. Despite a decrease in year-over-year total revenue of 29.6%, total revenue was still USD 56.2 million. Net income for the quarter was USD 1.4 million, a decrease of 86.0% compared to the same quarter in 2023.
Although these figures indicate a downturn in the company’s performance, it is still worth monitoring as ALECTOR may have untapped potential. Investors may want to look at the company’s recent trends and upcoming events to gain insight into where the stock price may be headed.
Related Posts
Recent Posts
